Drug and alcohol dependence reports · 2026
Relationship between extended-release buprenorphine adherence and reduced risk of return to use in patients with opioid use disorder: A retrospective claims data analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jerry Michelle, Venkat Divya, Flynn Courtney, Tran Anh Thu, Abdel-Sattar Maher, Mullen William, Lane Colleen
Аннотация
PURPOSE: To evaluate the association between adherence to monthly extended-release buprenorphine (BUP-XR) and reducing the risk of return to use among patients with opioid use disorder (OUD).
METHODS: This retrospective claims analysis included adult patients (age≥18 years) initiating monthly BUP-XR between 3/1/2019-12/31/2022 (index date=earliest BUP-XR claim date) in the Merative™ MarketScan® Commercial/Medicare/Medicaid Databases. Patients had continuous enrollment with medical/pharmacy/behavioral health benefits for 12 months pre-index (baseline period) and 12 months post-index (follow-up period). Patients were categorized to four mutually-exclusive groups: Group 1 (adherence [proportion of days covered; PDC≥0.8] to BUP-XR treatment); Group 2 (adherence to overall MOUD but BUP-XR PDC<0.8); Group 3 (non-adherence to overall MOUD and primarily treated with BUP-XR); Group 4 (non-adherence to overall MOUD and not primarily treated with BUP-XR). Descriptive and adjusted analyses compared the prevalence of return to use during follow-up for Group 1 (reference) to other groups.
RESULTS: Of 3400 patients, 19.8% had adherence to BUP-XR (Group 1) during the 12-month follow-up (20.9% in Group 2, 39.9% in Group 3, and 19.4% in Group 4). Compared to patients with BUP-XR adherence (Group 1), patients not meeting adherence criteria with BUP-XR were significantly more likely to return to use (adjusted odds ratios of 3.49 for Group 2, 3.30 for Group 3, and 8.08 for Group 4; all p < 0.001), including Group 2 patients who had BUP-XR PDC< 0.8 but had adherence to overall MOUD.
CONCLUSION: Adherence to monthly BUP-XR 100 mg or 300 mg in the 12 months following treatment initiation was associated with reduced odds of return to use compared to less consistent use of BUP-XR and continued adherence to other MOUD.
METHODS: This retrospective claims analysis included adult patients (age≥18 years) initiating monthly BUP-XR between 3/1/2019-12/31/2022 (index date=earliest BUP-XR claim date) in the Merative™ MarketScan® Commercial/Medicare/Medicaid Databases. Patients had continuous enrollment with medical/pharmacy/behavioral health benefits for 12 months pre-index (baseline period) and 12 months post-index (follow-up period). Patients were categorized to four mutually-exclusive groups: Group 1 (adherence [proportion of days covered; PDC≥0.8] to BUP-XR treatment); Group 2 (adherence to overall MOUD but BUP-XR PDC<0.8); Group 3 (non-adherence to overall MOUD and primarily treated with BUP-XR); Group 4 (non-adherence to overall MOUD and not primarily treated with BUP-XR). Descriptive and adjusted analyses compared the prevalence of return to use during follow-up for Group 1 (reference) to other groups.
RESULTS: Of 3400 patients, 19.8% had adherence to BUP-XR (Group 1) during the 12-month follow-up (20.9% in Group 2, 39.9% in Group 3, and 19.4% in Group 4). Compared to patients with BUP-XR adherence (Group 1), patients not meeting adherence criteria with BUP-XR were significantly more likely to return to use (adjusted odds ratios of 3.49 for Group 2, 3.30 for Group 3, and 8.08 for Group 4; all p < 0.001), including Group 2 patients who had BUP-XR PDC< 0.8 but had adherence to overall MOUD.
CONCLUSION: Adherence to monthly BUP-XR 100 mg or 300 mg in the 12 months following treatment initiation was associated with reduced odds of return to use compared to less consistent use of BUP-XR and continued adherence to other MOUD.